ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Zepbound — Worldwide revenue growth YoY by Quarter
Zepbound — Worldwide revenue growth YoY (%) (%)
Eli Lilly Zepbound — Worldwide revenue growth YoY: 46.0% in Q2 2026, down 126.0 pts from a year earlier.
Latest, Q2 2026
46.0%
Period ended Jun 30, 2026
Change on a year earlier
-126.0 pts
172.0% in Q2 2025
History
5 quarters
Since Q2 2025
Sources
5
Documents cited below
Where the Q2 2026 figure comes from
“|| Zepbound (1) | 4,873 | 55 | 4,928 | 3,381 | 46”
Source: Form 10-Q FY2026Q2 (filed 2026-08-05) ↗
Reported in Form 10-Q / 10-K MD&A & Form 8-K Releases.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Zepbound — Worldwide revenue growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 46.0% | -126.0 pts | Form 10-Q FY2026Q2 (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 80.0% | – | Form 10-Q FY2026Q1 (filed 2026-04-30) ↗ |
| Q4 2025 | Dec 31, 2025 | 123.0% | – | Earnings Release (Form 8-K FY2025Q4 EX-99.1) (filed 2026-02-04) ↗ |
| Q3 2025 | Sep 30, 2025 | 185.0% | – | Form 10-Q FY2025Q3 (filed 2025-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 172.0% | – | Form 10-Q FY2025Q2 (filed 2025-08-07) ↗ |
Cite this data
StockData. (2026). Eli Lilly Zepbound — Worldwide revenue growth YoY (%), quarterly Q2 2025–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-zepbound-yoy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.